PMV Pharmaceuticals, Inc.
Moat Score — PMV Pharmaceuticals, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | PMV's structurally selective, mutation-specific small-molecule design targeting p53 Y220C represents real, differentiated chemistry IP with FDA Fast Track designation, though it remains unproven at the approval stage. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | PMV has no manufacturing facilities of its own and relies on third parties for drug substance and companion diagnostics, giving it no production cost advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved product and rezatapopt still in pivotal Phase 2 trials, PMV has no current ability to price any product. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Precision oncology therapeutics carry no network effect — one patient's treatment does not increase rezatapopt's value to the next patient. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed product, there are no treating oncologists or patients to generate switching costs yet. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The p53 Y220C mutation affects only about 1% of cancers, a narrow enough population that it may not attract overwhelming competition even after approval, though the broader p53-targeting field (Jacobio, AstraZeneca, Novartis, and others) remains crowded. |